This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Miguel A. Álvarez-Avitia, MD
Advertisement
Articles by Miguel A. Álvarez-Avitia, MD
Advertisement
Latest Updated Articles
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaPublished: September 16th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
